James C. Gilbert - Concepedia

Author

James C. Gilbert

Also Known As

J C Gilbert, J. C. Gilbert, J. Gilbert, J.C. GILBERT, J.C. Gilbert, JAMES C. GILBERT, James C Gilbert, James C. Gilbert, James Gilbert, Petra Jilma-Stohlawetz

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Medical University of Vienna Archemix (United States)Children's National Guardian Industries (United States)Women & Children's Hospital of Buffalo

About

James C. Gilbert is an author at Medical University of Vienna specializing in medicine, pharmacology, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	25	1.3K
2	Health Sciences	4	4	292
3	Allergy	3	3	132
4	Anatomy	2	2	44
5	Social Sciences	1	1	11

James C. Gilbert

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers James C. Gilbert, Tia DeFeo-Fraulini, Renta Hutabarat, Circulation	2007	282
Appendicitis 2000: Variability in practice, outcomes, and resource utilization at thirty pediatric hospitals Kurt D. Newman, Todd A. Ponsky, Kory Kittle, Journal of Pediatric Surgery Appendicitis 2000Thirty Pediatric HospitalsPediatric Emergency MedicinePatient SafetyPediatrics	2003	237
Quantitation of transplanted hepatic mass necessary to cure the gunn rat model of hyperbilirubinemia Katsuhiro Asonuma, James C. Gilbert, James E. Stein, Journal of Pediatric Surgery Gunn Rat ModelTransplantationHepatologyHealth SciencesMedicine	1992	111
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial Ulrich Jäger, Shirley D’Sa, Christian Schörgenhofer, Blood	2018	108
The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale Robert P. Giugliano, L. Kristin Newby, Robert A. Harrington, American Heart Journal ThrombosisCardiovascular DiseaseCoronary Artery DiseaseClinical TrialsClinical Benefits	2005	88
Impact of bicycle helmet safety legislation on children admitted to a regional pediatric trauma center Shahid Shafi, James C. Gilbert, Fazlollah Loghmanee, Journal of Pediatric Surgery Patient SafetySafety SciencePediatricsSafety PolicyTransport Safety	1998	82
A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease Petra Paulinska, Petra Jilma‐Stohlawetz, James C. Gilbert, Thrombosis and Haemostasis ImmunologyPharmacotherapyType 2BRandomised Pilot TrialVon Willebrand Disease	2010	80
Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection—results from a first-in-patient phase 1 trial Farsad Eskandary, Bernd Jilma, Jakob Mühlbacher, American Journal of Transplantation	2017	80
The use of a bioactive skin substitute decreases length of stay for pediatric burn patients Jeffrey R. Lukish, Martin R. Eichelberger, Kurt D. Newman, Journal of Pediatric Surgery Bioactive Skin SubstitutePediatric Burn PatientsPediatricsSkin SubstituteBurn Management	2001	75
Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura Spero R. Cataland, Marie Scully, James Paskavitz, American Journal of Hematology	2010	74

Page 1